The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global heparin market reached a value of US$ 6.9 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 8.1 Billion by 2027, exhibiting a CAGR of 2.57% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
Heparin, denoted by the chemical formula C12H19NO20S3, is a sulfur-containing polysaccharide that acts as an anticoagulant or a blood thinner. It prevents the formation of blood clots inside blood vessels and is used for the treatment of heart conditions and unstable angina. It is also used in post-surgeries as well as during dialysis and blood transfusion. Heparin is usually injected directly into the muscle or the veins to break up clots and maintain smooth fluidity of the blood. Some common side-effects of using heparin include easy bruising and itchy skin with redness.
The rising prevalence of various medical ailments such as deep vein thrombosis (DVT) and pulmonary embolism (PE) is one of the key factors driving the global market. Also, heparin has been proven to be an extremely effective drug for venous thromboembolism and cardiovascular disorders (CVDs), which is contributing significantly to its market growth. Furthermore, biopharmaceutical companies are developing innovative medicines to enhance the therapeutic potential of heparin and reduce its side-effects. Availability of synthetic and semi-synthetic heparin mimetics that assist in treating various cancers, coagulation and inflammatory diseases is significantly increasing the adoption of the product. The market is further driven by the various advancements in the field of carbohydrate synthesis, which include building block preparation, coupling reactions and the development of convergent strategies. Moreover, increasing government funding toward improving healthcare facilities and extensive research and development (R&D) activities to develop heparin with ultra-low molecular weight for utilization in chemotherapy are also creating a positive outlook for the market.
IMARC Group’s latest report provides a deep insight into the global heparin market covering all its essential aspects. This ranges from macro overview of the market to micro details of the industry performance, recent trends, key market drivers and challenges, SWOT analysis, Porter’s five forces analysis, value chain analysis, etc. This report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the heparin market in any manner.
IMARC Group provides an analysis of the key trends in each sub-segment of the global heparin market, along with forecasts at the global and regional level from 2022-2027. Our report has categorized the market based on product, source, mode of administration, application, end-user and distribution channel.
Breakup by Product:
Breakup by Source:
Breakup by Mode of Administration:
Breakup by Application:
Breakup by End-User:
Breakup by Distribution Channel:
Breakup by Region:
The report has also analyzed the competitive landscape of the market with some of the key players being GlaxoSmithKline Plc, Shenzhen Hepalink Pharmaceutical Co., Ltd, Pfizer Inc., LEO Pharma A/S, Sanofi S.A., Dr. Reddy’s Laboratories Ltd., Teva Pharmaceutical Industries Ltd., Aspen Holdings, Baxter International Inc., Hebei Changshan Biochemical Pharmaceutical Co. Ltd., Sandoz International GmbH, Opocrin S.p.A., Sichuan Deebio Pharmaceutical Co., Ltd. and Dongying Tiandong Pharmaceutical Co., Ltd.
|Base Year of the Analysis||2021|
|Segment Coverage||Product, Source, Mode of Administration, Application, End-User, Distribution Channel, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Companies Covered||GlaxoSmithKline Plc, Shenzhen Hepalink Pharmaceutical Co., Ltd, Pfizer Inc., LEO Pharma A/S, Sanofi S.A., Dr. Reddy’s Laboratories Ltd., Teva Pharmaceutical Industries Ltd., Aspen Holdings, Baxter International Inc., Hebei Changshan Biochemical Pharmaceutical Co. Ltd., Sandoz International GmbH, Opocrin S.p.A., Sichuan Deebio Pharmaceutical Co., Ltd. and Dongying Tiandong Pharmaceutical Co., Ltd.|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at